ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium.
Giovanni RossiLodovica ZulloLuigi CerboneSimona CocoLuca LongoMarco TagliamentoMaria Giovanna Dal BelloSimona BoccardoAngela AlamaCarlo GenovaPublished in: Expert opinion on pharmacotherapy (2020)
Data from clinical trials available to date have discouraged the use of PARPi in association with chemotherapy or radiotherapy in NSCLC. The knowledge available to date opens the door to the use of PARPi in association with immunotherapy. In fact, the activity of these drugs would not be based only on direct cytotoxic action, but also on the modification of the intra-tumor microenvironment, in particular by increasing the expression of PD-L1 on tumor cells. This action might potentially enhance available treatments with a modest increase in toxicity.
Keyphrases
- clinical trial
- locally advanced
- poor prognosis
- early stage
- radiation therapy
- oxidative stress
- electronic health record
- squamous cell carcinoma
- randomized controlled trial
- machine learning
- radiation induced
- advanced non small cell lung cancer
- big data
- binding protein
- phase ii
- artificial intelligence
- anti inflammatory
- drug induced